Psoriatic Arthritis

EULAR Report: Ixekizumab Approved for Axial Spondyloarthritis

June 04, 2020

Eli Lilly announced this week that Taltz (ixekizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA). And, this week during the EULAR annual meeting, the company is reporting results from the 52-week SPIRIT phase 3b/4 trial for psoriatic arthritis comparing ixekizumab to adalimumab.

Psoriasis Cancer Prevalence is 4.7% New Research Shows

February 19, 2020

A systematic review and meta-analysis published today in JAMA Dermatology confirms that psoriasis patients have a slightly increased risk of cancer, specifically, keratinocyte cancer and lymphomas.

Apremilast Continues to Show Viability as Monotherapy

January 16, 2020

Psoriatic arthritis patients with moderate disease activity were more likely to reach treatment targets or low disease activity at week 52 with apremilast (Otezla, Celgene) than patients with high disease activity, researchers report in the January 7 issue of Arthritis Care and Research.

Secukinumab Benefits in Psoriatic Arthritis Persist for 5 Years

January 08, 2020

Secukinumab (Cosentyx, Novartis) provided sustained improvements through five years in the signs and symptoms of psoriatic arthritis with no new safety signals, say researchers recently writing in ACR Open Rheumatology.

Is Tofacitinib as Monotherapy Enough for Psoriatic Arthritis?

November 13, 2019

ACR Annual Meeting:  The use of methotrexate combined with or without the oral JAK inhibitor tofacitinib produced no clinically meaningful difference in 179 psoriatic arthritis patients from the OPAL Balance study, presented at ACR 2019 this week.

Guselkumab Safe, Efficient in Biologic-Naïve Patients with Active Psoriatic Arthritis

November 12, 2019

ACR Annual Meeting:  In patients with active psoriatic arthritis, who are biologic-naïve, guselkumab (Tremfya, Janssen) improved joint and skin symptoms, physical function, quality of life, and resolved enthesitis and dactylitis, according to a study presented at annual meeting of the American College of Rheumatology in Atlanta on November 12.

Nearly 90 Percent of PsA Patients Who Use Complementary Medicines Report Benefits

November 11, 2019

ACR Annual Meeting:  More than half of survey psoriatic arthritis patients say they have adopted complementary or alternative medicine strategies and most say they've experienced some benefit, researchers reported November 12 at the annual meeting of the American College of Rheumatology in Atlanta.

Ustekinumab Linked to Lower Serious Infection Rates in Psoriasis and Psoriatic Arthritis

November 11, 2019

ACR Annual Meeting:  Compared with seven other biologics and a phosphodiesterase-4 inhibitor, the anti-IL-12/23 biologic ustekinumab was associated with a generally lower risk of serious infection requiring hospitalization in psoriasis or psoriatic arthritis patients, researchers reported on November 12 at the American College of Rheumatology annual meeting in Atlanta.

Golimumab Study Shows Lasting Improvements in Psoriatic Arthritis

November 10, 2019

ACR Annual Meeting:  Intravenous golimumab produced lasting improvements in health-related quality of life for psoriatic arthritis patient one year post treatment, researchers reported on November 11 at the American College of Rheumatology annual meeting in Atlanta.

Low Radiographic Progression in Psoriatic Arthritis Sustained with Secukinumab

November 05, 2019

Secukinumab (Cosentyx, Novartis) provided sustained low rates of radiographic progression through 52 weeks in patients with active psoriatic arthritis, say researchers writing in Rheumatology this month.

x